Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
Brain
BioVie Issues Letter to Shareholders
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis...
Healthy Extracts’ Whitney Johns Launches Brain Activate ENERGY Gel Packs on WhitneyJohns.com
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell...
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral...
TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in...
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced...
SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat”...
Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated...
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE...
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and...
PatchMD Launch New Shopify Website To Keep Up With Demand For The 2022-2023 Holiday Season
Las Vegas, Nevada, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Founded by a team of experts with over 60 years of...
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"),...
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...